Preprint finds education, APOE status barely shift GLP-1 dementia estimates

The wire

1. 01Observational cohort of 14,364 All of Us participants with type 2 diabetes, mean follow-up 4.3 years, compared GLP-1 receptor agonist initiators with non-SGLT2 second-line therapy initiators.
2. 02Addresses a standing question about whether reported dementia benefits with GLP-1 drugs reflect confounding by socioeconomic status or genetic risk unmeasured in EHR data.
3. 03Authors say results do not exclude confounding in other populations or residual confounding; confidence intervals crossed 1 and the paper is a medRxiv preprint.

From the source

Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes

medRxiv : the preprint server for health sciences · 2026 Sep 8 · Wang J, Pederson AM, Flanders MD et al.